Majority of patients with colorectal cancer do not experience social difficulties

Share this content:

the ONA take:

Although the majority observe no difficulties, a portion of individuals diagnosed with colorectal cancer (CRC) do experience poor social outcomes.

Researchers based at the Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, United Kingdom, sent questionnaires  to all 12- to 36-month CRC survivors diagnosed in 2010 or 2011 and treated by the English National Health Service. The questionnaire assessed clinical data, sociodemographic information, and included the Social Difficulties Inventory.

The latter inventory is a 16-item scale of social distress that reviews everyday living conditions, self and others subscales, and related items.

Approximately 82% of the 21,802 respondents completed all social distress items. (Overall response rate of the 34,467 individuals contacted was 63.3%.)

Approximately 15% OF individuals reported experiencing social distress. Multivariable analysis indicated that having three or more long-term conditions was a strong precursor to social distress.

It was determined that the majority of individuals diagnosed with CRC experience no social distress, and that the risk factors (clinical and otherwise) can be used to target support for those who are more likely to experience social difficulties.

Elevated CSN6 may be prognostic for poor survival in patients with colorectal cancer
Although the majority observe no difficulties, a portion of individuals diagnosed with colorectal cancer do experience poor social outcomes.
Researchers sought to establish the prevalence and determinants of poor social outcomes after a diagnosis of colorectal cancer.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs